相似文献
1
Serum HDL-Cholesterol Level Does Not Influence Cardiovascular Event Rate under Sufficient Lowering of LDL-Cholesterol by Pitavatatin in Patients with Stable Coronary Artery Disease.
J Atheroscler Thromb. 2022 Jan 1;29(1):8-10. doi: 10.5551/jat.ED165. Epub 2021 Mar 24.
2
High-Density Lipoprotein Cholesterol and Cardiovascular Events in Patients with Stable Coronary Artery Disease Treated with Statins: An Observation from the REAL-CAD Study.
J Atheroscler Thromb. 2022 Jan 1;29(1):50-68. doi: 10.5551/jat.59881. Epub 2021 Jan 9.
3
Torcetrapib and atorvastatin.
N Engl J Med. 2005 Oct 6;353(14):1527-9; author reply 1527-9. doi: 10.1056/NEJMc055277.
4
Statins and regression of coronary atherosclerosis.
JAMA. 2007 May 23;297(20):2197; author reply 2197. doi: 10.1001/jama.297.20.2197-a.
5
Lipoproteins and cardiovascular risk.
Lancet. 2003 Jun 7;361(9373):1988-9; author reply 1989. doi: 10.1016/S0140-6736(03)13565-9.
6
7
Cholesterol, lipids, and statins.
Tex Heart Inst J. 2005;32(3):378-9.
8
Optimal lipids, statins, and dementia.
J Am Coll Cardiol. 2005 Mar 15;45(6):963-4; author reply 964-5. doi: 10.1016/j.jacc.2004.12.019.
9
LDL-Cholesterol is the King.
Angiology. 2009 Jun-Jul;60(3):387-8. doi: 10.1177/0003319709334121. Epub 2009 Jun 3.
10
Med could reverse arterial blockages.
Health News. 2006 Jul;12(7):13.
本文引用的文献
1
High-Density Lipoprotein Cholesterol and Cardiovascular Events in Patients with Stable Coronary Artery Disease Treated with Statins: An Observation from the REAL-CAD Study.
J Atheroscler Thromb. 2022 Jan 1;29(1):50-68. doi: 10.5551/jat.59881. Epub 2021 Jan 9.
2
High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial.
Circulation. 2018 May 8;137(19):1997-2009. doi: 10.1161/CIRCULATIONAHA.117.032615.
3
Trials and Tribulations of CETP Inhibitors.
Circ Res. 2018 Jan 5;122(1):106-112. doi: 10.1161/CIRCRESAHA.117.311978. Epub 2017 Oct 10.
4
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.
N Engl J Med. 2017 Sep 28;377(13):1217-1227. doi: 10.1056/NEJMoa1706444. Epub 2017 Aug 28.
5
Postprandial Hyperlipidemia and Remnant Lipoproteins.
J Atheroscler Thromb. 2017 Feb 1;24(2):95-109. doi: 10.5551/jat.RV16003. Epub 2016 Nov 8.
6
The Relationship between Very High Levels of Serum High-Density Lipoprotein Cholesterol and Cause-Specific Mortality in a 20-Year Follow-Up Study of Japanese General Population.
J Atheroscler Thromb. 2016 Jul 1;23(7):800-9. doi: 10.5551/jat.33449. Epub 2016 Feb 26.
7
Disposition into Adipose Tissue Determines Accumulation and Elimination Kinetics of the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Mice.
Drug Metab Dispos. 2016 Mar;44(3):428-34. doi: 10.1124/dmd.115.067736. Epub 2015 Dec 28.
8
HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
Am J Cardiovasc Drugs. 2011 Dec 1;11(6):411-7. doi: 10.2165/11594620-000000000-00000.
9
Comparison of preventive effect on cardiovascular events with different statins. -The CIRCLE study-.
Circ J. 2011;75(8):1951-9. doi: 10.1253/circj.cj-10-1163. Epub 2011 Jun 15.
10
Molecular mechanisms of HDL-cholesterol elevation by statins and its effects on HDL functions.
J Atheroscler Thromb. 2010 May;17(5):436-51. doi: 10.5551/jat.5405.
Zotero 插件